AU2008252964B2 - Triazol compounds for treating biofilm formation - Google Patents

Triazol compounds for treating biofilm formation Download PDF

Info

Publication number
AU2008252964B2
AU2008252964B2 AU2008252964A AU2008252964A AU2008252964B2 AU 2008252964 B2 AU2008252964 B2 AU 2008252964B2 AU 2008252964 A AU2008252964 A AU 2008252964A AU 2008252964 A AU2008252964 A AU 2008252964A AU 2008252964 B2 AU2008252964 B2 AU 2008252964B2
Authority
AU
Australia
Prior art keywords
lower alkyl
compound
cystic fibrosis
aeruginosa
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2008252964A
Other languages
English (en)
Other versions
AU2008252964A1 (en
Inventor
David Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38534753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008252964(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2008252964A1 publication Critical patent/AU2008252964A1/en
Application granted granted Critical
Publication of AU2008252964B2 publication Critical patent/AU2008252964B2/en
Priority to AU2012201134A priority Critical patent/AU2012201134B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008252964A 2007-05-22 2008-05-21 Triazol compounds for treating biofilm formation Expired - Fee Related AU2008252964B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012201134A AU2012201134B2 (en) 2007-05-22 2012-02-27 Triazol compounds for treating biofilm formation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07108650.8 2007-05-22
EP07108650A EP1994930A1 (en) 2007-05-22 2007-05-22 Triazol compounds for treating biofilm formation
PCT/EP2008/056231 WO2008142094A1 (en) 2007-05-22 2008-05-21 Triazol compounds for treating biofilm formation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012201134A Division AU2012201134B2 (en) 2007-05-22 2012-02-27 Triazol compounds for treating biofilm formation

Publications (2)

Publication Number Publication Date
AU2008252964A1 AU2008252964A1 (en) 2008-11-27
AU2008252964B2 true AU2008252964B2 (en) 2011-12-01

Family

ID=38534753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008252964A Expired - Fee Related AU2008252964B2 (en) 2007-05-22 2008-05-21 Triazol compounds for treating biofilm formation

Country Status (18)

Country Link
US (2) US8309590B2 (enExample)
EP (3) EP1994930A1 (enExample)
JP (1) JP5470245B2 (enExample)
KR (1) KR101519675B1 (enExample)
CN (2) CN103381271A (enExample)
AU (1) AU2008252964B2 (enExample)
BR (1) BRPI0811103A2 (enExample)
CA (1) CA2685112A1 (enExample)
CL (1) CL2008001469A1 (enExample)
IL (1) IL201832A (enExample)
MA (1) MA31388B1 (enExample)
MX (1) MX2009012628A (enExample)
NZ (1) NZ580735A (enExample)
RU (1) RU2478385C2 (enExample)
TN (1) TN2009000487A1 (enExample)
TW (1) TWI419690B (enExample)
WO (1) WO2008142094A1 (enExample)
ZA (1) ZA200907415B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
RU2646488C2 (ru) * 2016-04-25 2018-03-05 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОрГМУ Минздрава России) Средство для селективного влияния на биопленкообразование микроорганизмами
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN110448693A (zh) * 2019-07-30 2019-11-15 华东理工大学 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004438A (en) * 1991-12-31 1999-12-21 3M Innovative Properties Company Biofilm reduction sterilizer
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1997049397A1 (en) * 1996-06-26 1997-12-31 Sankyo Company, Limited Novel medicinal compositions of hydropyridines
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
WO2001070213A2 (en) 2000-03-23 2001-09-27 Influx, Inc. Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure
WO2002076439A2 (en) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
GB0205593D0 (en) * 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
US20040043052A1 (en) * 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
US7498292B2 (en) 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Med. Hypotheses, 2004, 63, 863-865. *
Nature 2000, 407, 762-764. *

Also Published As

Publication number Publication date
TN2009000487A1 (en) 2011-03-31
RU2009147297A (ru) 2011-06-27
MX2009012628A (es) 2009-12-07
JP5470245B2 (ja) 2014-04-16
US20100152101A1 (en) 2010-06-17
EP2253317A2 (en) 2010-11-24
AU2008252964A1 (en) 2008-11-27
KR101519675B1 (ko) 2015-05-12
BRPI0811103A2 (pt) 2014-12-09
NZ580735A (en) 2012-02-24
US8309590B2 (en) 2012-11-13
KR20100017153A (ko) 2010-02-16
JP2010527960A (ja) 2010-08-19
CN101678004A (zh) 2010-03-24
ZA200907415B (en) 2010-07-28
US8592473B2 (en) 2013-11-26
MA31388B1 (fr) 2010-05-03
EP1994930A1 (en) 2008-11-26
IL201832A0 (en) 2010-06-16
RU2478385C2 (ru) 2013-04-10
CL2008001469A1 (es) 2010-10-29
IL201832A (en) 2015-11-30
WO2008142094A1 (en) 2008-11-27
TWI419690B (zh) 2013-12-21
TW200913996A (en) 2009-04-01
EP2162130A1 (en) 2010-03-17
EP2253317A3 (en) 2011-03-16
CN103381271A (zh) 2013-11-06
WO2008142094A4 (en) 2009-01-29
CA2685112A1 (en) 2008-11-27
US20120329746A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
AU2008252964B2 (en) Triazol compounds for treating biofilm formation
WAISBREN et al. A clinical appraisal of neomycin
JP5469511B2 (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
US20070190033A1 (en) Bacteriophage-containing therapeutic agents
JP6228580B2 (ja) フルオロキノロン類を用いた細菌性肺感染症の治療方法。
CN103687598A (zh) 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物
EA003458B1 (ru) Усиление активности оксазолидиноновых антибактериальных агентов в результате применения производных аргинина
JP2010527960A5 (enExample)
JP2002500189A5 (enExample)
AU2012201134B2 (en) Triazol compounds for treating biofilm formation
US20060073156A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
HK1146223A (en) Triazol compounds for treating biofilm formation
WO2002022147A1 (en) Antibacterial combination comprising neem plant extract
AU2003303953A1 (en) Antibacterial pyrazole carboxylic acid hydrazides
Andersen et al. Pivmecillinam in the treatment of therapy resistant urinary tract infections: A comparison with pivmecillinam, pivampicillin and their combination
JP2908375B2 (ja) 非抗バクテリア性テトラサイクリン組成物
US10485805B2 (en) Finafloxacin for use in the treatment of urinary tract infections
WO2024231524A1 (en) Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and serine beta-lactamase inhibitor
WO2024231518A1 (en) Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and cyclic boronate beta-lactamase inhibitor
WO2024231522A1 (en) Therapy
HK40053249A (en) Use of rifamycin-quinolizidone coupling molecule and pharmaceutically acceptable salt thereof
JP2001097864A (ja) 呼吸管および尿路病原性細菌に対するフルオロキノリン化合物の使用方法
JP2001097891A (ja) 呼吸器系病原菌に対するフルオロキノロン化合物の使用法

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee